J&J stock weathers big sanction

Critics think Johnson & Johnson got off relatively easy when the company agreed last week to pay $2.2 billion to settle allegations that it marketed its profitable anti-psychotic drug Risperdal and two other drugs for uses not approved by the FDA.
Read more here.